Latest News
Oct 17, 2017

Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Monday, Nov. 6, 2017, at 10:30 a.m. ET, to review the company's financial results for the...

Oct 16, 2017

Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United States District Court for the Eastern District of Texas has issued a 135-page decision finding all asserted claims of the patents...

Oct 5, 2017

Mylan N.V. (NASDAQ, TASE: MYL) today announced that partner, Synthon, received marketing authorization approval in Europe for Glatiramer Acetate Injection 40 mg/mL, a therapeutically equivalent...

Oct 5, 2017

Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Moxifloxacin Hydrochloride in 0.8% Sodium Chloride Injection, 400 mg/250 mL (1.6 mg/mL) in 250 mL single-dose flexible bags, the...

Oct 4, 2017

Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the company has launched in the U.S. the first Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection that is an AP-rated...

View More


Search News Releases

Contact Mylan Communications

Global Communications 
724.514.1968
communications@mylan.com

Stay Connected